VKTX - Viking Therapeutics Inc Market Cap to Sales Volume

Corporate company logo of Viking Therapeutics Inc (VKTX)

Viking Therapeutics relies on external manufacturing capacities, minimizing risks through long-term contracts. The current P/S ratio clearly confirms market expectations, with the value stabilizing at . The asset's price action depends on FDA approval of the VK2735 drug, while Brian Lian's strategic course ensures prudent capital management and high clinical trial velocity.

VKTX: Viking Pharma P/S Multiple 07/04/2022 - 11/17/2026

Analytical breakdowns for Viking Therapeutics Corp (VKTX)

- share price and consensus valuation forecast:
Fundamental company analysis:Viking Therapeutics, Inc. - VKTX
Finished products of Viking Pharma

The P/S ratio relates market capitalization to sales volume, allowing for an assessment of business value relative to generated revenue and the identification of asset overheating. The price-to-sales multiple analysis for Viking Therapeutics (VKTX) reflects market expectations regarding the company's future pricing power in the obesity drug segment, where successful clinical trials could justify current premium valuations.

Competing companies

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price-to-Sales Ratio SUPN (Supernus)|CPRX (Catalyst Pharmaceuticals Inc) - P/S Multiple|DNLI: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio harmonybiosciences.com (HRMY)|Biohaven - Market Cap to Revenue Ratio|P/S Multiple AMLX (amylyx.com)|Trevi Pharma (TRVI) - Price to Sales|Praxis Corp - P/S Multiple|Anavex Corp (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Prothena Biosciences - Market Capitalization-to-Revenue Ratio|ALEC (alector.com) - P/S Multiple|Market Cap to Revenue Ratio ANNX (Annexon Biosciences)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune S.A. ACIU|Price-to-Revenue Coefficient Voyager Therapeutics (VYGR)|Neumora - P/S Multiple|Price-to-Sales Ratio SCLX|Tevogen Bio Inc. (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|CGTX (cogrx.com) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue